| Fallon Ann Clancy, PA | |
|
939 Caroline St, Port Angeles, WA 98362-3997 | |
| (360) 565-0999 | |
| (360) 565-9251 |
| Full Name | Fallon Ann Clancy |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 6 Years |
| Location | 939 Caroline St, Port Angeles, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023580461 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363AM0700X | Physician Assistant - Medical | (* (Not Available)) | Secondary |
| 363A00000X | Physician Assistant | PA60922624 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Olympic Medical Center | Port angeles, WA | Hospital |
| Jefferson Healthcare | Port townsend, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Olympic Medical Physicians | 9537172358 | 113 |
News Archive
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
As children spend more time tethered to screens, there is increasing concern about potential harm to their visual development. Ophthalmologists – physicians who specialize in medical and surgical eye care – are seeing a marked increase in children with dry eye and eye strain from too much screen time.
MD-A new culprit has been identified that likely plays a big role in the severity of asthma-a small protein chemokine called CCL26. These findings were published in the Journal of Leukocyte Biology and represent the first demonstration that CCL26 is a potent regulator of the migration of asthmatic eosinophils, commonly observed in asthmatic airways. Results from this discovery may lead to new drug targets for the treatment of asthma.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Fallon Ann Clancy, PA 907 Georgiana St, Port Angeles, WA 98362-3911 Ph: (360) 565-0999 | Fallon Ann Clancy, PA 939 Caroline St, Port Angeles, WA 98362-3997 Ph: (360) 565-0999 |
News Archive
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
As children spend more time tethered to screens, there is increasing concern about potential harm to their visual development. Ophthalmologists – physicians who specialize in medical and surgical eye care – are seeing a marked increase in children with dry eye and eye strain from too much screen time.
MD-A new culprit has been identified that likely plays a big role in the severity of asthma-a small protein chemokine called CCL26. These findings were published in the Journal of Leukocyte Biology and represent the first demonstration that CCL26 is a potent regulator of the migration of asthmatic eosinophils, commonly observed in asthmatic airways. Results from this discovery may lead to new drug targets for the treatment of asthma.
› Verified 9 days ago
Matthew Thomas James, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 234511 Hwy 101 West, Port Angeles, WA 98363 Phone: 360-452-6252 Fax: 360-452-6274 | |
Matthew Kiddle, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 907 Georgiana St, Port Angeles, WA 98362 Phone: 360-565-0999 Fax: 360-457-1599 | |
Ms. Robin Sterin, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 907 Georgiana St, Port Angeles, WA 98362 Phone: 360-565-0999 Fax: 360-457-1599 | |
John F Calf Looking, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 243511 W Highway 101, Port Angeles, WA 98363 Phone: 360-452-6252 Fax: 360-452-6274 | |
Sara Steffen, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 907 Georgiana St, Port Angeles, WA 98362 Phone: 360-565-0999 Fax: 360-565-0901 | |
Ryan Dunning, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 939 Caroline St, Port Angeles, WA 98362 Phone: 360-417-7000 |